As analysts and investors digested the implications of the colossal combination of Gilead Sciences Inc. and Pharmasset Inc. on the hepatitis C virus (HCV) market, some began to speculate on the logical next question: What comes next?
Agios Pharmaceuticals bagged $78 million in an oversubscribed Series C, signaling that the financing gate – if not floodgate – remains open for emerging biotechs.
Idenix Pharmaceuticals Inc. took advantage of the tailwind in its stock, which on Tuesday hit a 52-week high of $7.38, by pricing a public offering disclosed one day earlier.
Bellicum Pharmaceuticals Inc., whose name loosely translates from Latin as "call to war," is developing technology that seeks out and eliminates the donor T cells that cause graft-vs.-host disease (GVHD), an often-fatal complication of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute leukemia.
Privately held biotech Signum Biosciences Inc. signaled its intention to play in a bigger sandbox on Wednesday by signing an agreement with GlaxoSmithKline (China) R&D Co. Ltd. to advance Signum's phosphatase screening technology, which targets the phosphoprotein phosphatase 2A (PP2A) as a key mechanism in Alzheimer's disease (AD).
Rempex Pharmaceuticals Inc., formed in June to acquire the human, financial and clinical assets unrelated to Aeroquin from Mpex Pharmaceuticals Inc., has attracted a commitment of up to $67.5 million to advance the development of treatments for resistant Gram-negative infections.
Cancer immunotherapy firm TVAX Biomedical Inc. became the latest biotech to line up this year for an initial public offering, filing an S-1 on Monday and seeking to raise $40 million.
One week after shares of NPS Pharmaceuticals Inc. were drubbed over safety concerns about the GLP-2 analogue Gattex (teduglutide) in short bowel syndrome, the company sought a ray of sunshine with positive top-line results from its pivotal Phase III REPLACE study of Natpara (NPSP558), a bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients. (See BioWorld Today, Nov. 1, 2011.)In an intent-to-treat analysis, NPS reported that 53 percent (48/90) of Natpara-treated patients achieved the primary endpoint vs.
Despite a growing revenue stream – $64.3 million in the third quarter compared to $20.2 million in the same period a year earlier and nearly 30 percent more than the second quarter – Dendreon Corp.
